bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures 1 through 3 from Bone Marrow–Derived Mesenchymal Stromal Cells Promote Survival and Drug Resistance in Tumor Cells
Authors: Bergfeld Scott A. , Blavier Laurence , DeClerck Yves A.
Published: April 2023

PDF - 74K, Supplemental Figure S1. Expansion of LL/2 tumor cells exposed to BMMSC; Supplemental Figure S2. Cell cycle progression in 4T1 tumor cells exposed to BMMSC; Supplemental Figure S3. Stress-induced apoptosis in LL/2 tumor cells exposed to BMMSC.
Supplementary Figures 1 and 2 from MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer
Authors: Muñoz-Galván Sandra , Gutierrez Gabriel , Perez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure S1 - MAP17 interacts with the proteasome system (A) Protein-Protein interaction network of MAP17. Supplementary Figure S2 - Gene ontology analysis of the enriched biological process terms for MAP17-interacting proteins.
Supplementary Figure 1 from The NADPH Oxidase Inhibitor Imipramine-Blue in the Treatment of Burkitt Lymphoma
Authors: Klingenberg Marcel , Becker Jürgen , Eberth Sonja , Kube Dieter , Wilting Jörg
Published: April 2023

PDF - 1109K, Blood and lymphatic vessel density in experimental BL2B95 tumors treated with IB in the CAM model.
Supplementary Materials and Methods, Table 1 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
Authors: Jiang Ning , Wang Dongsheng , Hu Zhongliang , Shin Hyung Ju C. , Qian Guoqing , Rahman Mohammad Aminur , Zhang Hongzheng , Amin A.R.M. Ruhul , Nannapaneni Sreenivas , Wang Xiaojing , Chen Zhengjia , Garcia Gabriela , MacBeath Gavin , Shin Dong M. , Khuri Fadlo R. , Ma Jun , Chen Zhuo G. , Saba Nabil F.
Published: April 2023

PDF file - 171KB, Synergistic Indices of combination treatment with MM-121 and cetuximab in different assays.
Supplementary Figure 4 from MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer
Authors: Muñoz-Galván Sandra , Gutierrez Gabriel , Perez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure S4 - MAP17 overexpression is related to a better prognosis of multiple myeloma patients.
Supplementary Figure 3 from MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer
Authors: Muñoz-Galván Sandra , Gutierrez Gabriel , Perez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure S3 - MAP17 overexpression correlates with advances stages of breast tumors.
Supplementary Table 4 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
Authors: Mori Masamichi , Ueno Yoko , Konagai Satoshi , Fushiki Hiroshi , Shimada Itsuro , Kondoh Yutaka , Saito Rika , Mori Kenichi , Shindou Nobuaki , Soga Takatoshi , Sakagami Hideki , Furutani Takashi , Doihara Hitoshi , Kudoh Masafumi , Kuromitsu Sadao
Published: April 2023

PDF file - 59K, Inhibitory activity of ASP3026 against EML4-ALK with gatekeeper-residue mutation L1196M.
Supplementary Figure 3 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
Authors: Jiang Ning , Wang Dongsheng , Hu Zhongliang , Shin Hyung Ju C. , Qian Guoqing , Rahman Mohammad Aminur , Zhang Hongzheng , Amin A.R.M. Ruhul , Nannapaneni Sreenivas , Wang Xiaojing , Chen Zhengjia , Garcia Gabriela , MacBeath Gavin , Shin Dong M. , Khuri Fadlo R. , Ma Jun , Chen Zhuo G. , Saba Nabil F.
Published: April 2023

PDF file - 195KB, The CM combination inhibits HER3 and EGFR activation.
Supplementary Table 1 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
Authors: Mori Masamichi , Ueno Yoko , Konagai Satoshi , Fushiki Hiroshi , Shimada Itsuro , Kondoh Yutaka , Saito Rika , Mori Kenichi , Shindou Nobuaki , Soga Takatoshi , Sakagami Hideki , Furutani Takashi , Doihara Hitoshi , Kudoh Masafumi , Kuromitsu Sadao
Published: April 2023

PDF file - 82K, Inhibitory activity of ASP3026 and crizotinib against various TKs.
Supplementary Figure 1 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
Authors: Jiang Ning , Wang Dongsheng , Hu Zhongliang , Shin Hyung Ju C. , Qian Guoqing , Rahman Mohammad Aminur , Zhang Hongzheng , Amin A.R.M. Ruhul , Nannapaneni Sreenivas , Wang Xiaojing , Chen Zhengjia , Garcia Gabriela , MacBeath Gavin , Shin Dong M. , Khuri Fadlo R. , Ma Jun , Chen Zhuo G. , Saba Nabil F.
Published: April 2023

PDF file - 96KB, Sensitivity of HNSCC cell lines to MM-121 and cetuximab.
Supplementary Figure 2 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
Authors: Mori Masamichi , Ueno Yoko , Konagai Satoshi , Fushiki Hiroshi , Shimada Itsuro , Kondoh Yutaka , Saito Rika , Mori Kenichi , Shindou Nobuaki , Soga Takatoshi , Sakagami Hideki , Furutani Takashi , Doihara Hitoshi , Kudoh Masafumi , Kuromitsu Sadao
Published: April 2023

PDF file - 6669K, Antitumor activities of ASP3026 in hEML4-ALK transgenic mice.
Supplementary Table 2 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
Authors: Unger Gretchen M. , Kren Betsy T. , Korman Vicci L. , Kimbrough Tyler G. , Vogel Rachel I. , Ondrey Frank G. , Trembley Janeen H. , Ahmed Khalil
Published: April 2023

PDF - 53K, Hematological profile in FaDu metastatic spleen study mice 3 days post-treatment.
Supplemental Table 1 from Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth
Authors: Gritsina Galina , Xiao Fang , O'Brien Shane W. , Gabbasov Rashid , Maglaty Marisa A. , Xu Ren-Huan , Thapa Roshan J. , Zhou Yan , Nicolas Emmanuelle , Litwin Samuel , Balachandran Siddharth , Sigal Luis J. , Huszar Dennis , Connolly Denise C.
Published: April 2023

Supplemental Table 1. Differentially expressed genes in AZD1480 treated tumors vs. vehicle treated controls (2-fold change and p<0.01 cutoff).
Supplementary Figure 1 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
Authors: Unger Gretchen M. , Kren Betsy T. , Korman Vicci L. , Kimbrough Tyler G. , Vogel Rachel I. , Ondrey Frank G. , Trembley Janeen H. , Ahmed Khalil
Published: April 2023

PDF - 828K, Interrogation of an HNC Affymetrix U-133a microarray database for s50-TBG-RNAi-CK2-related proteins in human HNC tumor vs. normal oral mucosa.
Supplementary Table 1 from Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
Authors: Tan Nguyen , Wong Maureen , Nannini Michelle A. , Hong Rebecca , Lee Leslie B. , Price Stephen , Williams Karen , Savy Pierre Pascal , Yue Peng , Sampath Deepak , Settleman Jeffrey , Fairbrother Wayne J. , Belmont Lisa D.
Published: April 2023

PDF file - 39K, Summary of Combination Matrices for Navitoclax and G-963 in Pancreatic Cancer Cell Lines. The data reflect the average of three independent runs performed in quadruplicate
Supplementary Figure 4 from Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
Authors: Tan Nguyen , Wong Maureen , Nannini Michelle A. , Hong Rebecca , Lee Leslie B. , Price Stephen , Williams Karen , Savy Pierre Pascal , Yue Peng , Sampath Deepak , Settleman Jeffrey , Fairbrother Wayne J. , Belmont Lisa D.
Published: April 2023

PDF file - 581K, Correlative Biomarker Analysis. A) Western blots illustrating baseline levels of total Bad and phospho-S-112 Bad. Correlative analysis of Bliss sums and baseline levels of B) phospho-S-112 Bad (Spearman ρ = -0.46; P = 0.02)
Supplementary Figure Legends, Supplementary Table 1, and Supplementary Figures 1 through 8 from Metallothionein 1G and Zinc Sensitize Human Colorectal Cancer Cells to Chemotherapy
Authors: Arriaga Juan M. , Greco Angela , Mordoh José , Bianchini Michele
Published: April 2023

PDF - 1320K, Contains Legends to Supplementary Figures; Supplementary Table 1: sequences for primers and siRNAs; Supplementary Figure 1: IC50 curves for chemoresistant cell lines; Supplementary Figure 2: Proliferation and dose-response curves for MT1G+ clones, as well as cell cycle analysis results; Supplementary Figure 3: MTs and labile zinc induction by extracellular zinc; Supplementary Figure 4: MTs immunofluorescence after chemotherapy or zinc treatments; Supplementary Figure 5: Western Blot of subcellular fractions; Supplementary Figure 6: Zinc transporter expression after chemotherapy; Supplementary Figure 7: Expression of p53 and NF-KB target genes after OXA treatment; Supplementary Figure 8: Cytotoxicity of zinc chloride.
Supplementary Figure 1 from Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
Authors: Tan Nguyen , Wong Maureen , Nannini Michelle A. , Hong Rebecca , Lee Leslie B. , Price Stephen , Williams Karen , Savy Pierre Pascal , Yue Peng , Sampath Deepak , Settleman Jeffrey , Fairbrother Wayne J. , Belmont Lisa D.
Published: April 2023

PDF file - 115K, Synthetic route for G-963
Supplementary Table 1 from Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside–Nucleoside Analogue Radiosensitization
Authors: Magin Simon , Papaioannou Maria , Saha Janapriya , Staudt Christian , Iliakis George
Published: April 2023

Supplementary Table 1. Sensitizer enhancement ratios at different concentrations of araA
Supplementary Figures 1 - 7, Tables 1 - 4 from REST Negatively and ISGF3 Positively Regulate the Human STAT1 Gene in Melanoma
Authors: Amalraj James , Cutler Samuel J. , Ghazawi Ibtisam , Boyle Glen M. , Ralph Stephen J.
Published: April 2023

PDF file - 675K, Supplementary Figure 1. Characterization of an ISRE in the human STAT1 gene promoter. Supplementary Figure 2. ChIP assay demonstrates binding of REST to the STAT1 RE-1 element in melanoma cell lines. Supplementary Figure 3. Full-length, uncropped gel image from Fig. 5A of REST mRNA and 18S rRNA levels analysed in MM96 and INS-1 cells by RT-PCR. Supplementary Figure 4. Full-length, uncropped blot images from Fig. 5B of A. REST, and B. α-tubulin protein levels determined in MM96 and INS-1 cells by western blotting. Supplementary Figure 5. Full-length, uncropped gel image from Fig. 7A of REST mRNA and 18S rRNA levels determined by RT-PCR in SK-Mel-28 and MM96 cells. Supplementary Figure 6. Full-length, uncropped images of western blot from Fig. 7B showing REST and STAT1 protein levels detected in SK-Mel-28 and MM96 cells Supplementary Figure 7. The same blot as in Suppl. Fig. 6, stripped and reprobed with α-tubulin antibody. Non-specific background blotch is visible in lane 7. Relevant bands and molecular weights are indicated by arrows in the figure.
Supplementary Figure 5 from Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside–Nucleoside Analogue Radiosensitization
Authors: Magin Simon , Papaioannou Maria , Saha Janapriya , Staudt Christian , Iliakis George
Published: April 2023

Supplementary Figure 5. Effect of time-point of analysis after transfection on araA-mediated inhibition of HRR in U2OS 282C cells
Supplementary Figure 2 from Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside–Nucleoside Analogue Radiosensitization
Authors: Magin Simon , Papaioannou Maria , Saha Janapriya , Staudt Christian , Iliakis George
Published: April 2023

Supplementary Figure 2. Inhibition of DNA replication in A549 cells as measured by 3H-thymidine (3H-TdR) incorporation
Supplementary Figure 1 from Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside–Nucleoside Analogue Radiosensitization
Authors: Magin Simon , Papaioannou Maria , Saha Janapriya , Staudt Christian , Iliakis George
Published: April 2023

Supplementary Figure 1. Growth curve of A549 cells
Supplementary Figure Legends from Frequent Loss of NISCH Promotes Tumor Proliferation and Invasion in Ovarian Cancer via Inhibiting the FAK Signal Pathway
Authors: Li Jing , He Xiaoying , Dong Ruofan , Wang Yuan , Yu Jinjin , Qiu Haifeng
Published: April 2023

Figure S1. Representative electrophoresis images for promoter hypermethylation and LOH of NISCH.Figure S2. The flow cytometry profiles of cell cycle analysis with NISCH overexpressed or knockdown. Figure S3. The mRNA expression of NISCH in a panel of 45 ovarian cancer tissues in Lu's study.
Supplementary Figure 3 from Frequent Loss of NISCH Promotes Tumor Proliferation and Invasion in Ovarian Cancer via Inhibiting the FAK Signal Pathway
Authors: Li Jing , He Xiaoying , Dong Ruofan , Wang Yuan , Yu Jinjin , Qiu Haifeng
Published: April 2023

The mRNA expression of NISCH in a panel of 45 ovarian cancer tissues in Lu's study.
Supplementary Figure 2 from Frequent Loss of NISCH Promotes Tumor Proliferation and Invasion in Ovarian Cancer via Inhibiting the FAK Signal Pathway
Authors: Li Jing , He Xiaoying , Dong Ruofan , Wang Yuan , Yu Jinjin , Qiu Haifeng
Published: April 2023

The flow cytometry profiles of cell cycle analysis with NISCH overexpressed or knockdown.
Supplementary methods from PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy
Authors: Su Yu-Cheng , Cheng Ta-Chun , Leu Yu-Ling , Roffler Steve R. , Wang Jaw-Yuan , Chuang Chih-Hung , Kao Chien-Han , Chen Kai-Chuan , Wang Hsin-Ell , Cheng Tian-Lu
Published: April 2023

Supplementary methods. Chemical Synthesis of TrapG probes
Supplementary Figure S1 from PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy
Authors: Su Yu-Cheng , Cheng Ta-Chun , Leu Yu-Ling , Roffler Steve R. , Wang Jaw-Yuan , Chuang Chih-Hung , Kao Chien-Han , Chen Kai-Chuan , Wang Hsin-Ell , Cheng Tian-Lu
Published: April 2023

Supplementary Figure S1. In vivo imaging of endogenous β-glucuronidase by TrapG probes
Supplementary figures 1 through 9, supplementary tables 1 through 6, and supplementary materials from IMGN853, a Folate Receptor-α (FRα)–Targeting Antibody–Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors
Authors: Ab Olga , Whiteman Kathleen R. , Bartle Laura M. , Sun Xiuxia , Singh Rajeeva , Tavares Daniel , LaBelle Alyssa , Payne Gillian , Lutz Robert J. , Pinkas Jan , Goldmacher Victor S. , Chittenden Thomas , Lambert John M.
Published: April 2023

Supplemental Figure S1. Activity of anti-FRα clones in an indirect cytotoxicity assay. Supplemental Figure S2. The antigen-dependent cell-mediated cytotoxic activity of M9346A antibody against Igrov-1 cells. Supplemental Figure S3. Activity of the M9346A antibody against KB xenograft tumors. Supplemental Figure S4. The bystander cytotoxic activity of IMGN853. Supplemental Figure S5. In vitro cytotoxicity of IMGN853 against KB cells (short exposure). Supplemental Figure S6. In vitro cytotoxicity of IMGN853, M9346A-SMCCDM1 and non-targeting human IgG1-SMCC-DM1 against KB cells (continuous exposure). Supplemental Figure S7. Catabolites of IMGN853 formed in KB cells in vitro. Supplemental Figure S8. Comparison of 3[H]-M9346A antibody and 3[H]-IMGN853 conjugate processing. Figure S9. IMGN853 activity against KB xenograft tumors. Supplementary Tables. Supplementary Methods.
Supplementary Figure 5 from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
Authors: Smith Rosamund C. , Cramer Martin S. , Mitchell Pamela J. , Capen Andrew , Huber Lysiane , Wang Rong , Myers Laura , Jones Bryan E. , Eastwood Brian J. , Ballard Darryl , Hanson Jeff , Credille Kelly M. , Wroblewski Victor J. , Lin Boris K. , Heuer Josef G.
Published: April 2023

Supplementary Figure 5. Loss of body weight, muscle mass and strength in the PC3 tumor model.
Supplementary Table 3 from LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
Authors: King Constance , Diaz H. Bruce , McNeely Samuel , Barnard Darlene , Dempsey Jack , Blosser Wayne , Beckmann Richard , Barda David , Marshall Mark S.
Published: April 2023

Supplementary Table S3. Induction of DNA damage by LY2606368 is not caused by caspase-dependent apoptotic DNA fragmentation
Supplementary Table 2 from LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
Authors: King Constance , Diaz H. Bruce , McNeely Samuel , Barnard Darlene , Dempsey Jack , Blosser Wayne , Beckmann Richard , Barda David , Marshall Mark S.
Published: April 2023

upplementary Table S2. Protein kinases sensitive to LY2606368 with an IC50 less than 10,000 nM
Supplementary Figure 2 from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
Authors: Smith Rosamund C. , Cramer Martin S. , Mitchell Pamela J. , Capen Andrew , Huber Lysiane , Wang Rong , Myers Laura , Jones Bryan E. , Eastwood Brian J. , Ballard Darryl , Hanson Jeff , Credille Kelly M. , Wroblewski Victor J. , Lin Boris K. , Heuer Josef G.
Published: April 2023

Supplementary Figure 2. LSN2478185 increases body weight and muscle mass in non-tumor-bearing mice in the presence of gemcitabine.
Supplementary Figure 1 from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
Authors: Smith Rosamund C. , Cramer Martin S. , Mitchell Pamela J. , Capen Andrew , Huber Lysiane , Wang Rong , Myers Laura , Jones Bryan E. , Eastwood Brian J. , Ballard Darryl , Hanson Jeff , Credille Kelly M. , Wroblewski Victor J. , Lin Boris K. , Heuer Josef G.
Published: April 2023

Supplementary Figure 1. LSN2478185 and LY2495655 neutralize 1nM myostatin in an SBE luciferase assay in HEK-293 cells.
Supplementary Materials and Methods and Supplementary Figure Legends from LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
Authors: King Constance , Diaz H. Bruce , McNeely Samuel , Barnard Darlene , Dempsey Jack , Blosser Wayne , Beckmann Richard , Barda David , Marshall Mark S.
Published: April 2023

This file contains the supplementary Materials and Methods section, supplementary references, legends for all supplementary figures and descriptions of all of the supplementary tables.
Supplementary Figures 1 through 7 from LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
Authors: King Constance , Diaz H. Bruce , McNeely Samuel , Barnard Darlene , Dempsey Jack , Blosser Wayne , Beckmann Richard , Barda David , Marshall Mark S.
Published: April 2023

This file contains all supplementary figures: Figure S1. LY2606368 is an ATP competitive inhibitor of CHK1. Figure S2. LY2606368 is a potent catalytic and phenotypic inhibitor of CHK1. Figure S3. LY2606368 inhibits DNA damage-dependent autophosphorylation of CHK2. Figure S4. LY2606368 does not inhibit RSK activity in cells Figure S5. Treatment of Calu-6 lung cancer cells with LY2606368 results in rapid accumulation of DNA strand breaks in early S-phase. Figure S6. Timelapse photomicroscopy of LY2606368 treated HeLa cells confirms that S-phase transit is required for aberrant mitosis and cell death. Figure S7. Staurosporine causes rapid appearance of apoptotic TUNEL staining, but not H2AX serine 139 phosphorylation.
Supplementary Figure 2 from Cancer-Targeted BikDD Gene Therapy Elicits Protective Antitumor Immunity against Lung Cancer
Authors: Sher Yuh-Pyng , Liu Shih-Jen , Chang Chun-Mien , Lien Shu-Pei , Chen Chien-Hua , Han Zhenbo , Li Long-Yuan , Chen Jin-Shing , Wu Cheng-Wen , Hung Mien-Chie
Published: April 2023

Supplementary Figure 2 from Cancer-Targeted BikDD Gene Therapy Elicits Protective Antitumor Immunity against Lung Cancer
Data Supplement from Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Sharma Arati , Kuzu Omer F. , Robertson Gavin P.
Published: April 2023

Supplemental Figure S3. Loading efficiency of leelamine in the nanoliposomal formulation was measured by UV-visible spectrophotometry following centrifugation using 10kDa a Centricon filter to remove free drug from the nanoparticle. Methanol was used as the reference blank. Percentage drug incorporated in the nanoliposome was calculated as the free drug(s)/total drug(s)x100.
Supplementary Figure 1 from Cancer-Targeted BikDD Gene Therapy Elicits Protective Antitumor Immunity against Lung Cancer
Authors: Sher Yuh-Pyng , Liu Shih-Jen , Chang Chun-Mien , Lien Shu-Pei , Chen Chien-Hua , Han Zhenbo , Li Long-Yuan , Chen Jin-Shing , Wu Cheng-Wen , Hung Mien-Chie
Published: April 2023

Supplementary Figure 1 from Cancer-Targeted BikDD Gene Therapy Elicits Protective Antitumor Immunity against Lung Cancer
Data Supplement from Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Sharma Arati , Kuzu Omer F. , Robertson Gavin P.
Published: April 2023

Supplemental Figure S4. The in vitro release of tritium labeled leelamine from Nanolipolee-007 was measured at room temperature using a molecular weight cut off 25 kDa dialysis membrane. 68.32% of leelamine was released from Nanolipolee-007 within 36 hours.
Supplemental Tables and Supplemental Figure Legends from Utilization of the Eμ-Myc Mouse to Model Heterogeneity of Therapeutic Response
Authors: Rempel Rachel E. , Jiang Xiaolei , Fullerton Paul , Tan Tuan Zea , Ye Jieru , Lau Jieying Amelia , Mori Seiichi , Chi Jen-Tsan , Nevins Joseph R. , Friedman Daphne R.
Published: April 2023

Table S1: Datasets used for genomic analyses Table S2: Parameters used for genomic signature generation and application with BinReg algorithm Table S3: Gene Ontology Biological Processes Terms that are significantly upregulated in Cluster 1 vs. Cluster 2 Eµ-Myc lymphomas Table S4: Distribution of Eµ-Myc lymphomas with regard to B-cell maturation stage, determined by genomic analyses Table S5: Distribution of Eµ-Myc lymphomas with regard to phenotype Table S6: mRNA expression of selected NF-κB target genes in Cluster 1 and Cluster 2 Eμ-Myc lymphomas
Data Supplement from Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Sharma Arati , Kuzu Omer F. , Robertson Gavin P.
Published: April 2023

Supplemental Table S2. Leelamine hydrochloride was encapsulated into a nanoliposome prepared by combining egg L-α-Phosphatidylcholine (ePC) and 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N- [Methoxy(Polyethylene glycol)-2000] ammonium salt (DPPE-PEG-2000) in chloroform at different ratios. Biophysical characterizations involving size, zeta potential, efficacy, stability and loading efficiency of the drug in the nanoparticle was also examined.
Figure S5 from Utilization of the Eμ-Myc Mouse to Model Heterogeneity of Therapeutic Response
Authors: Rempel Rachel E. , Jiang Xiaolei , Fullerton Paul , Tan Tuan Zea , Ye Jieru , Lau Jieying Amelia , Mori Seiichi , Chi Jen-Tsan , Nevins Joseph R. , Friedman Daphne R.
Published: April 2023

Figure S5: Assessment of NF-κB pathway in the two Eµ-Myc lymphoma clusters
Data Supplement from Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Sharma Arati , Kuzu Omer F. , Robertson Gavin P.
Published: April 2023

Supplemental methods and legends
Figure S4 from Utilization of the Eμ-Myc Mouse to Model Heterogeneity of Therapeutic Response
Authors: Rempel Rachel E. , Jiang Xiaolei , Fullerton Paul , Tan Tuan Zea , Ye Jieru , Lau Jieying Amelia , Mori Seiichi , Chi Jen-Tsan , Nevins Joseph R. , Friedman Daphne R.
Published: April 2023

Figure S4: Progression free survival after treatment, stratified by Eµ-Myc lymphoma cluster and Trp53 mutation status
Supplementary Tables 1-2 from NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification
Authors: Yoshida Yasuyuki , Ozawa Tomoko , Yao Tsun-Wen , Shen Wang , Brown Dennis , Parsa Andrew T. , Raizer Jeffrey J. , Cheng Shi-Yuan , Stegh Alexander H. , Mazar Andrew P. , Giles Francis J. , Sarkaria Jann N. , Butowski Nicholas , Nicolaides Theodore , James C. David
Published: April 2023

Supplementary Table 1: Selected IC50 results from NT113 screen of 130 tyrosine kinases; Supplementary Table 2: Inhibitor Tissue Concentrations.
Figure S2 from Utilization of the Eμ-Myc Mouse to Model Heterogeneity of Therapeutic Response
Authors: Rempel Rachel E. , Jiang Xiaolei , Fullerton Paul , Tan Tuan Zea , Ye Jieru , Lau Jieying Amelia , Mori Seiichi , Chi Jen-Tsan , Nevins Joseph R. , Friedman Daphne R.
Published: April 2023

Figure S2: Analysis of Trp53 and the p53 pathway in Eµ-Myc lymphomas
Supplementary Figures 1-3 and Supplementary Materials and Methods from Antibody against Granulin–Epithelin Precursor Sensitizes Hepatocellular Carcinoma to Chemotherapeutic Agents
Authors: Wong Nicholas C.L. , Cheung Phyllis F.Y. , Yip Chi Wai , Chan Kui Fat , Ng Irene Oi-Lin , Fan Sheung Tat , Cheung Siu Tim
Published: April 2023

Supplementary Figure S1: IgG negative control demonstrated no added effect on the chemotherapy induced apoptosis; Supplementary Figure S2: Secretory GEP levels in Hep3B and Huh7 culture supernatants; Supplementary Figure S3: Combined GEP antibody and high dose cisplatin eradicated the established intrahepatic xenografts.
Supplemental figure legends from Histone Deacetylase 6 Represents a Novel Drug Target in the Oncogenic Hedgehog Signaling Pathway
Authors: Dhanyamraju Pavan Kumar , Holz Philipp Simon , Finkernagel Florian , Fendrich Volker , Lauth Matthias
Published: April 2023

Legends to figures S1-S6
Supplementary Methods and Results from Enigmol: A Novel Sphingolipid Analogue with Anticancer Activity against Cancer Cell Lines and In vivo Models for Intestinal and Prostate Cancer
Authors: Symolon Holly , Bushnev Anatoliy , Peng Qiong , Ramaraju Harsha , Mays Suzanne G. , Allegood Jeremy C. , Pruett Sarah T. , Sullards M. Cameron , Dillehay Dirck L. , Liotta Dennis C. , Merrill Alfred H.
Published: April 2023

Supplementary Methods and Results from Enigmol: A Novel Sphingolipid Analogue with Anticancer Activity against Cancer Cell Lines and In vivo Models for Intestinal and Prostate Cancer
Supplementary Figures 1-6 from Enigmol: A Novel Sphingolipid Analogue with Anticancer Activity against Cancer Cell Lines and In vivo Models for Intestinal and Prostate Cancer
Authors: Symolon Holly , Bushnev Anatoliy , Peng Qiong , Ramaraju Harsha , Mays Suzanne G. , Allegood Jeremy C. , Pruett Sarah T. , Sullards M. Cameron , Dillehay Dirck L. , Liotta Dennis C. , Merrill Alfred H.
Published: April 2023

Supplementary Figures 1-6 from Enigmol: A Novel Sphingolipid Analogue with Anticancer Activity against Cancer Cell Lines and In vivo Models for Intestinal and Prostate Cancer
Figure S1 from Histone Deacetylase 6 Represents a Novel Drug Target in the Oncogenic Hedgehog Signaling Pathway
Authors: Dhanyamraju Pavan Kumar , Holz Philipp Simon , Finkernagel Florian , Fendrich Volker , Lauth Matthias
Published: April 2023

This file contains experiments about the role of HDAC6 in cilia formation.
Supplementary Materials and Methods; Supplementary Figures S1-S5; and Supplementary References from Therapeutic Targeting of Angiogenesis with a Recombinant CTT Peptide–Endostatin Mimic–Kringle 5 Protein
Authors: Wang Houbin , Yang Zhigang , Gu Jun
Published: April 2023

Figure S1. In vitro beta-casein degradation analysis (MMP-9); Figure S2. AARPalpha induces endothelial apoptosis; Figure S3. RK5, AARPalpha/AARPbeta exerted no inhibitory effects on non-endothelial cells; Figure S4. Detection of Serum AST, ALT, BUN and creatine; Figure S5. Body weights of mice xenografted with LLC and treated with RK5, AARPalpha, AARPbeta (25 mg/kg), paclitaxel (10 mg/kg).
Supplementary Table 1 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Authors: Jo Jae-Cheol , Choi Eun Kyoung , Shin Jae-Sik , Moon Jai-Hee , Hong Seung-Woo , Lee Ha-Reum , Kim Seung-Mi , Jung Soo-A , Lee Dae-Hee , Jung Seang Hwan , Lee Sun-Hye , Kim Jeong Eun , Kim Kyu-pyo , Hong Yong Sang , Suh Young-Ah , Jang Se Jin , Choi Eun Kyung , Lee Jung Shin , Jin Dong-Hoon , Kim Tae Won
Published: April 2023

The Hepatitis B (HBV) or C virus (HCV) infectious status on primary cancer cells
Supplementary Figure legend from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Authors: Jo Jae-Cheol , Choi Eun Kyoung , Shin Jae-Sik , Moon Jai-Hee , Hong Seung-Woo , Lee Ha-Reum , Kim Seung-Mi , Jung Soo-A , Lee Dae-Hee , Jung Seang Hwan , Lee Sun-Hye , Kim Jeong Eun , Kim Kyu-pyo , Hong Yong Sang , Suh Young-Ah , Jang Se Jin , Choi Eun Kyung , Lee Jung Shin , Jin Dong-Hoon , Kim Tae Won
Published: April 2023

Supplementary Figure legend
Supplementary Figure 5 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Authors: Jo Jae-Cheol , Choi Eun Kyoung , Shin Jae-Sik , Moon Jai-Hee , Hong Seung-Woo , Lee Ha-Reum , Kim Seung-Mi , Jung Soo-A , Lee Dae-Hee , Jung Seang Hwan , Lee Sun-Hye , Kim Jeong Eun , Kim Kyu-pyo , Hong Yong Sang , Suh Young-Ah , Jang Se Jin , Choi Eun Kyung , Lee Jung Shin , Jin Dong-Hoon , Kim Tae Won
Published: April 2023

Expression of phospho-Met and FGFR in TMAs of tumor samples from HCC patients.
Supplementary Figure 1 from Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
Authors: Zahonero Cristina , Aguilera Pilar , Ramírez-Castillejo Carmen , Pajares Marta , Bolós Maria Victoria , Cantero Diana , Perez-Nuñez Angel , Hernández-Laín Aurelio , Sánchez-Gómez Pilar , Sepúlveda Juan Manuel
Published: April 2023

Effect of dacomitinib in the in vivo growth of GBMs.
supplementary figure legends from A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways
Authors: Rios-Doria Jonathan , Sabol Darrin , Chesebrough Jon , Stewart Dave , Xu Linda , Tammali Ravinder , Cheng Li , Du Qun , Schifferli Kevin , Rothstein Ray , Leow Ching Ching , Heidbrink-Thompson Jenny , Jin Xiaofang , Gao Changshou , Friedman Jay , Wilkinson Brandy , Damschroder Melissa , Pierce Andrew J. , Hollingsworth Robert E. , Tice David A. , Michelotti Emil F.
Published: April 2023

supplmentary figure legends
Supplementary Figure 2 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Authors: Jo Jae-Cheol , Choi Eun Kyoung , Shin Jae-Sik , Moon Jai-Hee , Hong Seung-Woo , Lee Ha-Reum , Kim Seung-Mi , Jung Soo-A , Lee Dae-Hee , Jung Seang Hwan , Lee Sun-Hye , Kim Jeong Eun , Kim Kyu-pyo , Hong Yong Sang , Suh Young-Ah , Jang Se Jin , Choi Eun Kyung , Lee Jung Shin , Jin Dong-Hoon , Kim Tae Won
Published: April 2023

Effects of FGFR3 or FGFR4 on the sensitivities of PHA665752-treated HCC cell lines.
Supplementary Figure 1 from Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity
Authors: Jo Jae-Cheol , Choi Eun Kyoung , Shin Jae-Sik , Moon Jai-Hee , Hong Seung-Woo , Lee Ha-Reum , Kim Seung-Mi , Jung Soo-A , Lee Dae-Hee , Jung Seang Hwan , Lee Sun-Hye , Kim Jeong Eun , Kim Kyu-pyo , Hong Yong Sang , Suh Young-Ah , Jang Se Jin , Choi Eun Kyung , Lee Jung Shin , Jin Dong-Hoon , Kim Tae Won
Published: April 2023

Inhibition of cell growth and downstream signaling molecules of HCC cell lines by MET or pan-FGFR inhibitor.
Supplementary Materials and Methods, Figures S1-5 and Tables S1-8 from Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity
Authors: Yin Yiyuan , Djakovic Stevan , Marsters Scot , Tien Janet , Peng Jing , Tremayne Jarrod , Lee Genee , Neve Richard M. , Wu Yan , Merchant Mark , Ashkenazi Avi , Carter Paul J.
Published: April 2023

Supplementary Materials and Methods, Figures S1-5 and Tables S1-8. Supplementary Materials and Methods: More detailed description of Materials and Methods for experiments. Figure S1: Structural analysis of the FGFR3-IIIb and R3Mab complex. Figure S2: Sequence analysis of the CDR H2 of selected FGFR2-positive clones. Figure S3: Superimposition of crystal structures of FGFR2-D2:2B.1.3 and FGFR3-D2D3:R3Mab. Figure S4: in vitro and in vivo studies of the 2B.1 antibody variants using the breast cancer cell line MFM-223x2.2. Figure S5: FGFR2 and FGFR3 expressions in gastric cancer cell line SNU-16. Table S1: Library design for recruiting FGFR2 binding specificity for R3Mab. Table S2: Library design for removing FGFR4 binding specificity from 2B.1.3. Table S3: Sequence identities between human FGFR. Table S4: Bidning affinities of selected 2B.1 variants for FGFR2 and FGFR3. Table S5: X-ray crystallography data collection and refinement statistics. Table S6: Binding affinities of R3Mab and 2B.1.3 for the D2 alone and D2D3 constructs of FGFR2 and FGFR3. Table S7: Residue differences between FGFR2 and FGFR4 at the positions making potential contacts with 2B.1.3. Table S8: 2B.1.3 variants that retain FGFR2 binding and show diminished binding to FGFR4.
Supplementary Table 1 from Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2
Authors: Freiberger Sandra N. , Cheng Phil F. , Iotzova-Weiss Guergana , Neu Johannes , Liu Qinxiu , Dziunycz Piotr , Zibert John R. , Dummer Reinhard , Skak Kresten , Levesque Mitchell P. , Hofbauer Günther F.L.
Published: April 2023

Selection of further investigated targets.
Supplementary Fig. 6 from Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2
Authors: Freiberger Sandra N. , Cheng Phil F. , Iotzova-Weiss Guergana , Neu Johannes , Liu Qinxiu , Dziunycz Piotr , Zibert John R. , Dummer Reinhard , Skak Kresten , Levesque Mitchell P. , Hofbauer Günther F.L.
Published: April 2023

Time course experiment for gene expression analysis of IL13RA2 and IL1R2.
Supplemental Figure S2 from Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species–Dependent Targeting of Specificity Protein Transcription Factors
Authors: Hedrick Erik , Crose Lisa , Linardic Corinne M. , Safe Stephen
Published: April 2023

Supplemental Figure S2. Sp knockdown inhibits growth induced apoptosis and decreases RMS cell invasion.
Supplementary Fig. 5 from Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2
Authors: Freiberger Sandra N. , Cheng Phil F. , Iotzova-Weiss Guergana , Neu Johannes , Liu Qinxiu , Dziunycz Piotr , Zibert John R. , Dummer Reinhard , Skak Kresten , Levesque Mitchell P. , Hofbauer Günther F.L.
Published: April 2023

ERK is activated after IM treatment in a PKC-dependent manner.
Supplemental Figure S1 from Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species–Dependent Targeting of Specificity Protein Transcription Factors
Authors: Hedrick Erik , Crose Lisa , Linardic Corinne M. , Safe Stephen
Published: April 2023

Supplemental Figure S1. HDAC inhibitors induce apoptosis and decrease Sp proteins.
Supplementary Fig. 4 from Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2
Authors: Freiberger Sandra N. , Cheng Phil F. , Iotzova-Weiss Guergana , Neu Johannes , Liu Qinxiu , Dziunycz Piotr , Zibert John R. , Dummer Reinhard , Skak Kresten , Levesque Mitchell P. , Hofbauer Günther F.L.
Published: April 2023

Gene expression analysis of IM-treated primary keratinocytes and patient-derived SCC cells; pathways analysis; validation of specific genes
Supplementary Tables 1-7 from Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition
Authors: Mehta Monal , Khan Atif , Danish Shabbar , Haffty Bruce G. , Sabaawy Hatem E.
Published: April 2023

Supplementary Tables 1-7. Supplementary Table 1. Antibodies and conditions used for IF, IHC, flow cytometry and western blotting; Supplementary Table 2. Multiple comparisons in treatment effects adjusted for type of cell lines of U87 or U373 using Tukey adjustments; Supplementary Table 3. Primary GBM cells display distinct viabilities after treatment; Supplementary Table 4. Comparisons of treatment type of primary GBM cells revealed highly statistically significant differences; Supplementary Table 5. Colony formation is impaired with radiation when combined with AKT-i treatment in primary GBM; Supplementary Table 6. Comparison of colony formation after primary GBM cell treatments; Supplementary Table 7. Comparison of NESTIN expression upon treatment effects adjusted for type of primary GBM cells.
Supplementary Fig. 2 from Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2
Authors: Freiberger Sandra N. , Cheng Phil F. , Iotzova-Weiss Guergana , Neu Johannes , Liu Qinxiu , Dziunycz Piotr , Zibert John R. , Dummer Reinhard , Skak Kresten , Levesque Mitchell P. , Hofbauer Günther F.L.
Published: April 2023

Conformation of knock-down for siRNA experiments.
Supplementary Fig. 1 from Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2
Authors: Freiberger Sandra N. , Cheng Phil F. , Iotzova-Weiss Guergana , Neu Johannes , Liu Qinxiu , Dziunycz Piotr , Zibert John R. , Dummer Reinhard , Skak Kresten , Levesque Mitchell P. , Hofbauer Günther F.L.
Published: April 2023

Chemical structure of ingenol mebutate. Confirmation of inhibition by MEK and ERK inhibitor,
Supplementary Table 5 from A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors
Authors: Kendra Kari L. , Plummer Ruth , Salgia Ravi , O'Brien Mary E. R. , Paul Elaine M. , Suttle A. Benjamin , Compton Natalie , Xu Chun-Fang , Ottesen Lone H. , Villalona-Calero Miguel A.
Published: April 2023

Investigator-assessed best confirmed response to treatment with pazopanib and paclitaxel
Supplementary Table Legends from MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations
Authors: Sogabe Shunsuke , Togashi Yosuke , Kato Hiroaki , Kogita Akihiro , Mizukami Takuro , Sakamoto Yoichi , Banno Eri , Terashima Masato , Hayashi Hidetoshi , de Velasco Marco A. , Sakai Kazuko , Fujita Yoshihiko , Tomida Shuta , Yasuda Takushi , Takeyama Yoshifumi , Okuno Kiyotaka , Nishio Kazuto
Published: April 2023

The captions of Supplementary Tables 1 and 2.
Supplementary Table 2 from MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations
Authors: Sogabe Shunsuke , Togashi Yosuke , Kato Hiroaki , Kogita Akihiro , Mizukami Takuro , Sakamoto Yoichi , Banno Eri , Terashima Masato , Hayashi Hidetoshi , de Velasco Marco A. , Sakai Kazuko , Fujita Yoshihiko , Tomida Shuta , Yasuda Takushi , Takeyama Yoshifumi , Okuno Kiyotaka , Nishio Kazuto
Published: April 2023

Supplementary Table 2: Patient characteristics.
Supplementary Table 2 from A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors
Authors: Kendra Kari L. , Plummer Ruth , Salgia Ravi , O'Brien Mary E. R. , Paul Elaine M. , Suttle A. Benjamin , Compton Natalie , Xu Chun-Fang , Ottesen Lone H. , Villalona-Calero Miguel A.
Published: April 2023

Pharmacokinetic data for a cohort 1 patient with hepatotoxicity dose-limiting toxicity
Supplementary Table 1 from MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations
Authors: Sogabe Shunsuke , Togashi Yosuke , Kato Hiroaki , Kogita Akihiro , Mizukami Takuro , Sakamoto Yoichi , Banno Eri , Terashima Masato , Hayashi Hidetoshi , de Velasco Marco A. , Sakai Kazuko , Fujita Yoshihiko , Tomida Shuta , Yasuda Takushi , Takeyama Yoshifumi , Okuno Kiyotaka , Nishio Kazuto
Published: April 2023

Supplementary Table 1: Primers for sequencing and mutagenesis.
Supplementary Table 1 from A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors
Authors: Kendra Kari L. , Plummer Ruth , Salgia Ravi , O'Brien Mary E. R. , Paul Elaine M. , Suttle A. Benjamin , Compton Natalie , Xu Chun-Fang , Ottesen Lone H. , Villalona-Calero Miguel A.
Published: April 2023

Liver function tests for a cohort 1 patient with a hepatotoxicity dose-limiting toxicity
Supplemntary Figure 3 from Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78
Authors: Mo Lihong , Bachelder Robin E. , Kennedy Margaret , Chen Po-Han , Chi Jen-Tsan , Berchuck Andrew , Cianciolo George , Pizzo Salvatore V.
Published: April 2023

Optimization of ascites treatment conditions
Supplementary information from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
Authors: Ju Huai-Qiang , Gocho Takeshi , Aguilar Mitzi , Wu Min , Zhuang Zhuo-Nan , Fu Jie , Yanaga Katsuhiko , Huang Peng , Chiao Paul J.
Published: April 2023

Supplementary information. Supplementary Materials and Methods
Supplementary Table 1 from Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78
Authors: Mo Lihong , Bachelder Robin E. , Kennedy Margaret , Chen Po-Han , Chi Jen-Tsan , Berchuck Andrew , Cianciolo George , Pizzo Salvatore V.
Published: April 2023

Selected genes
Supplementary figure S3 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
Authors: Ju Huai-Qiang , Gocho Takeshi , Aguilar Mitzi , Wu Min , Zhuang Zhuo-Nan , Fu Jie , Yanaga Katsuhiko , Huang Peng , Chiao Paul J.
Published: April 2023

Supplementary figure S3. PEITC-induced selective killing of PDAC cells with minimal toxicity to HPDE cells and nude mice.
Supplementary Table S1 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation
Authors: Ju Huai-Qiang , Gocho Takeshi , Aguilar Mitzi , Wu Min , Zhuang Zhuo-Nan , Fu Jie , Yanaga Katsuhiko , Huang Peng , Chiao Paul J.
Published: April 2023

Supplementary Table S1. Real-time PCR primer sequences of assessed genes.
Supplementary Figure 2 from Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78
Authors: Mo Lihong , Bachelder Robin E. , Kennedy Margaret , Chen Po-Han , Chi Jen-Tsan , Berchuck Andrew , Cianciolo George , Pizzo Salvatore V.
Published: April 2023

Ascites from ovarian cancer-bearing mice contributes to a faster progression of the cancer.
Supplementary Figure 1 from Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78
Authors: Mo Lihong , Bachelder Robin E. , Kennedy Margaret , Chen Po-Han , Chi Jen-Tsan , Berchuck Andrew , Cianciolo George , Pizzo Salvatore V.
Published: April 2023

Characterization of ID8 cell line
Supplementary Figures 1 through 9 from Pseudogene PTENP1 Functions as a Competing Endogenous RNA to Suppress Clear-Cell Renal Cell Carcinoma Progression
Authors: Yu Gan , Yao Weimin , Gumireddy Kiranmai , Li Anping , Wang Ji , Xiao Wei , Chen Ke , Xiao Haibing , Li Heng , Tang Kun , Ye Zhangqun , Huang Qihong , Xu Hua
Published: April 2023

Supplementary Figure 1: PTENP1 and PTEN expression were decreased in human ccRCC samples. Supplementary Figure 2: PTENP1 expression in ACHN and SN12PM6 cells. Supplementary Figure 3: PTENP1 expression activated AKT in ACHN and SN12PM6 cells. Supplementary Figure 4: miR-21 expression in ACHN and SN12PM6 cells. Supplementary Figure 5: PTEN expression in ACHN and SN12PM6 cells. Supplementary Figure 6: 5-10 fold overexpression of PTENP1 increased PTEN expression and suppressed cell proliferation, migration and invasion. Supplementary Figure 7: PTENP1 functions and regulation of PTEN are DICER dependent. Supplementary Figure 8: 5'AZA increased PTENP1 and PTEN expression and suppressed cell proliferation, migration and invasion. Supplementary Figure 9: Cisplatin and gemcitabine treatment increased PTENP1 expression.
Supplemental Figure 4 from ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
Authors: Regina Anthony , Demeule Michel , Tripathy Sasmita , Lord-Dufour Simon , Currie Jean-Christophe , Iddir Mustapha , Annabi Borhane , Castaigne Jean-Paul , Lachowicz Jean E.
Published: April 2023

Immunodetection of An2 and anti-HER2 by WB after immunoprecipitation of ANG4043 with anti-human Fc agarose beads. Mice bearing BT-474 cell tumors were treated with vehicle or ANG4043 (10 mg/kg). After 4hrs, mice were perfused with saline, brains were collected and homogenized, and human IgGs immunoprecipitated. WBs were then performed under reducing conditions to detect the presence of An2 (top panel) or humanized anti-HER2 mAb (bottom panel).
Supplementary Text from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma
Authors: Kong Li Ren , Chua Kian Ngiap , Sim Wen Jing , Ng Hsien Chun , Bi Chonglei , Ho Jingshan , Nga Min En , Pang Yin Huei , Ong Weijie Richard , Soo Ross Andrew , Huynh Hung , Chng Wee Joo , Thiery Jean-Paul , Goh Boon Cher
Published: April 2023

Supplementary Methods Supplementary Table Captions and legends for Supplementary Figures S1 -S11; Supplementary Table S1: Differentially regulated genes in both cisplatin-resistant and -sensitive phenotypes after cisplatin treatment (fold change > 1.5, P < 0.05); Supplementary Table S2: Baseline characteristics of the head and neck squamous cell carcinoma (HNSCC)population, classified according to the p-ERK1/2 scoring.
Supplementary Figure S9 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma
Authors: Kong Li Ren , Chua Kian Ngiap , Sim Wen Jing , Ng Hsien Chun , Bi Chonglei , Ho Jingshan , Nga Min En , Pang Yin Huei , Ong Weijie Richard , Soo Ross Andrew , Huynh Hung , Chng Wee Joo , Thiery Jean-Paul , Goh Boon Cher
Published: April 2023

MEK inhibition improves in vivo efficacy of cisplatin in SCC xenografts.
Supplementary Tables 1-7 from Gene Expression Profiling Provides Insights into Pathways of Oxaliplatin-Related Sinusoidal Obstruction Syndrome in Humans
Authors: Rubbia-Brandt Laura , Tauzin Sébastien , Brezault Catherine , Delucinge-Vivier Céline , Descombes Patrick , Dousset Bertand , Majno Pietro E. , Mentha Gilles , Terris Benoit
Published: April 2023

Supplementary Tables 1-7 from Gene Expression Profiling Provides Insights into Pathways of Oxaliplatin-Related Sinusoidal Obstruction Syndrome in Humans
Supplementary Figure S8 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma
Authors: Kong Li Ren , Chua Kian Ngiap , Sim Wen Jing , Ng Hsien Chun , Bi Chonglei , Ho Jingshan , Nga Min En , Pang Yin Huei , Ong Weijie Richard , Soo Ross Andrew , Huynh Hung , Chng Wee Joo , Thiery Jean-Paul , Goh Boon Cher
Published: April 2023

MEK inhibition enhances colony inhibition in lung squamous cell carcinoma (SCC) cells.